Abbott Laboratories

Abbott Laboratories

ABTยทNYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Mรฉniรจre's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026
3Y+16.0%
5Y+20.0%
10Y+58.0%
3Y-10.0%
5Y-14.0%
10Y+6.0%
3Y+43.0%
5Y+60.0%
10Y+155.0%
abt

Abbott Laboratories Funding & Solvency Profile

ABT ยท NYSE
Cash & Cash Equivalents8.52B
Net Receivables7.93B
Inventory6.49B
Other Current Assets2.64B
Total Current Assets26 B
Property, Plant & Equipment12.94B
Goodwill & Intangible Assets29.56B
Long-Term Investments918.00M
Other Non-Current Assets17.30B
Total Non-Current Assets31 B
Total Assets
86.71B

Financial Health Analysis

Current Ratio

1.58x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.64x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

10 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

30% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Abbott Laboratories Balance Sheet

ABT โ€ข NYSE

Abbott Laboratories Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
ASSETS
CURRENT ASSETS
8.5B
7.6B
6.9B
9.9B
9.8B
6.8B
3.9B
3.8B
9.4B
18.6B
5B
4.1B
3.5B
10.8B
6.8B
7.3B
8.8B
4.1B
2.5B
521.2M
417M
351M
383M
288M
450M
310M
280M
242M
203M
155M
1.1B
397M
4.6B
4.4B
1.3B
0.0
1.1B
967.6M
364.4M
852.2M
8.9B
8B
7.3B
10.2B
10.2B
7.1B
4.1B
4.1B
9.6B
18.8B
6.1B
4.5B
8.1B
15.2B
8.1B
7.3B
9.9B
5.1B
2.8B
1.4B
7.9B
6.9B
6.6B
6.2B
6.5B
6.4B
5.4B
5.2B
5.2B
3.2B
3.4B
3.6B
4B
7.6B
7.7B
7.2B
6.5B
5.5B
4.9B
4.2B
7.9B
6.9B
6.6B
6.2B
6.5B
6.4B
5.4B
5.2B
5.2B
3.2B
3.4B
3.6B
4B
7.6B
7.7B
7.2B
6.5B
5.5B
4.9B
4.2B
6.5B
6.2B
6.6B
6.2B
5.2B
5B
4.3B
3.8B
3.6B
2.4B
2.6B
2.6B
2.7B
3.8B
3.3B
3.2B
3.3B
2.8B
3B
2.8B
2.6B
2.6B
2.3B
2.7B
2.3B
1.9B
1.8B
1.6B
1.7B
2.3B
2B
2.9B
4.5B
4.7B
4.7B
4.6B
3.6B
3.7B
3.3B
2.9B
26B
23.7B
22.7B
25.2B
24.2B
20.4B
15.7B
14.6B
20.1B
26.8B
14.2B
15.3B
19.2B
31.3B
23.8B
22.3B
23.3B
17B
14B
11.3B
NON-CURRENT ASSETS
12.9B
11.7B
11.3B
10.3B
10.1B
10.1B
9B
7.6B
7.6B
5.7B
5.7B
5.9B
5.9B
8.1B
7.9B
8B
7.6B
7.2B
7.5B
6.9B
24B
23.1B
23.7B
22.8B
23.2B
23.7B
23.2B
23.3B
24B
7.7B
9.6B
10.1B
9.8B
15.8B
15.7B
15.9B
13.2B
10B
10.1B
9.4B
5.5B
6.6B
8.8B
10.5B
12.7B
14.8B
17B
18.9B
21.5B
4.5B
5.6B
6.2B
5.7B
8.6B
10B
12.2B
6.3B
5.2B
5.7B
6.4B
29.6B
29.8B
32.5B
33.3B
36B
38.5B
40.2B
42.2B
45.5B
12.2B
15.2B
16.3B
15.5B
24.4B
25.7B
28.1B
19.5B
15.1B
15.8B
15.9B
918M
886M
799M
766M
903M
1B
931M
897M
883M
2.9B
4B
229M
119M
274M
378.2M
302M
1.1B
1.1B
1.1B
1.2B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
4B
4.4B
4.8B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
17.3B
15.4B
6B
4.9B
4B
2.4B
2.1B
1.9B
2.1B
3.3B
492M
3B
2.2B
3.2B
2.6B
1.9B
1B
1.9B
1.2B
867.1M
60.7B
57.8B
50.5B
49.2B
51B
52.1B
52.2B
52.5B
56.1B
28.2B
29.8B
30.2B
23.7B
35.9B
36.5B
38.3B
29.3B
25.4B
25.7B
24.9B
86.7B
81.4B
73.2B
74.4B
75.2B
72.5B
67.9B
67.2B
76.3B
55B
44B
43.8B
43B
67.2B
60.3B
60.6B
52.6B
42.4B
39.7B
36.2B
LIABILITIES
CURRENT LIABILITIES
5.9B
4.8B
4.8B
5B
4.7B
4.3B
3.5B
3.3B
2.7B
1.4B
1.5B
1.3B
1.2B
2.5B
2.2B
2.8B
1.7B
2.2B
1.3B
1.4B
4.2B
4.2B
4.3B
4.6B
4.4B
3.9B
3.3B
3B
2.4B
1.2B
1.1B
1.1B
1B
1.8B
1.7B
1.5B
1.3B
1.4B
1.2B
1.2B
1.7B
594M
492M
343M
306M
362M
226M
305M
309M
188M
430M
270M
175M
655M
514.9M
1.3B
442.1M
805.4M
80.4M
262.3M
1.7B
1.7B
1.6B
1.6B
1.6B
1.4B
1.2B
1.2B
1.2B
752M
746M
776M
906M
1.4B
1.3B
1.3B
1.1B
1B
859.8M
807.3M
3.3B
1.8B
1.3B
2.5B
999M
461M
1.7B
207M
714M
1.3B
3.1B
4.4B
3.2B
2.4B
3.4B
6.4B
5.2B
2.7B
2.7B
5.4B
569M
594M
492M
343M
306M
362M
226M
305M
309M
188M
430M
270M
175M
655.4M
514.9M
1.3B
442.1M
805.4M
54.7M
46.9M
5.5B
5.9B
6.1B
6.5B
5.8B
5.7B
4.5B
4.3B
4.3B
3.2B
3.8B
3.9B
4.2B
7B
8.6B
6.7B
5B
5.7B
4.2B
4.3B
16.5B
14.2B
13.8B
15.5B
13.1B
11.9B
10.9B
9B
8.9B
6.7B
9.2B
10.5B
9.5B
13.3B
15.5B
17.3B
13B
11.6B
9.1B
12B
NON-CURRENT LIABILITIES
10.8B
12.6B
13.6B
14.5B
17.3B
18.5B
16.7B
19.4B
27.2B
20.7B
5.9B
3.4B
3.4B
18.1B
12B
12.5B
11.3B
8.7B
9.5B
7B
2B
1.4B
1.2B
1.8B
2.1B
2.1B
2.1B
2.1B
2B
2.7B
3.6B
3.5B
466M
710M
703M
1.1B
165M
0.0
0.0
0.0
3.7B
4.5B
4.8B
4.7B
5.7B
6.1B
6.2B
6B
7B
4.3B
4.1B
4.8B
4.3B
8.3B
7.5B
6.9B
4.9B
4.6B
3.3B
3.2B
17.4B
19.4B
20.5B
22B
26.1B
27.6B
25.7B
27.4B
36.2B
27.6B
13.5B
11.7B
8.2B
27.1B
20.3B
20.5B
16.3B
13.3B
12.8B
10.2B
931M
896M
949M
943M
956M
902M
755M
8.1B
0.0
0.0
0.0
0.0
4.8B
9,056.2B
8,230.7B
7,199.9B
5,202.1B
4.6B
0.0
0.0
33.9B
33.5B
34.4B
37.5B
39.2B
39.5B
36.6B
36.5B
45.2B
31.9B
19.9B
19.6B
17.7B
40.4B
35.8B
37B
29.5B
24.9B
21.9B
22.1B
SHAREHOLDERS' EQUITY
-17.2B
-16.8B
-16B
-15.2B
-11.8B
-10B
-10.1B
-10B
-10.2B
-10.8B
-10.6B
-8.7B
-6.8B
-5.6B
-3.7B
-3.9B
-3.3B
-2.6B
-1.2B
-195.2M
25.5B
25.2B
24.9B
24.7B
24.5B
24.1B
23.9B
23.5B
23.2B
13B
12.7B
12.4B
12B
11.8B
9.8B
8.7B
8.3B
7.4B
6.1B
4.3B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
13B
0.0
12.4B
0.0
11.8B
9.8B
8.7B
8.3B
7.4B
6.1B
4.3B
49.8B
47.3B
37.6B
35.3B
31.5B
27.6B
25.8B
24.6B
24B
25.6B
25.8B
22.9B
22B
24.2B
20.9B
18.9B
17.1B
13.8B
10.8B
9.6B
-6B
-7.9B
-7.8B
-8.1B
-8.4B
-8.9B
-8.5B
-7.6B
-6.1B
-7.3B
-6.7B
-5.1B
-2B
-3.6B
-2.6B
-1.4B
854.1M
-1.2B
2.1B
389.8M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-13B
0.0
-12.4B
0.0
-11.8B
-9.8B
-8.5B
0.0
-7.4B
0.0
0.0
52.1B
47.7B
38.6B
36.7B
35.8B
32.8B
31.1B
30.5B
30.9B
20.5B
21.2B
21.5B
25.2B
26.7B
24.4B
22.7B
23.1B
17.5B
17.8B
14.1B
52.8B
47.9B
38.8B
36.9B
36B
33B
31.3B
30.7B
31.1B
20.7B
21.3B
21.6B
25.3B
26.8B
24.5B
22.8B
23.2B
17.5B
17.8B
14.1B
641M
237M
224M
219M
222M
219M
213M
198M
201M
179M
115M
113M
96M
92.3M
86.3M
88.3M
43.1M
39.1M
0.0
0.0
SUMMARY
86.7B
81.4B
73.2B
74.4B
75.2B
72.5B
67.9B
67.2B
76.3B
55B
44B
43.8B
43B
67.2B
60.3B
60.6B
52.6B
42.4B
39.7B
36.2B
1.3B
1.2B
1.2B
1.1B
1.4B
1.3B
1.2B
1.1B
1.1B
3.1B
5.2B
626M
4.7B
4.6B
1.7B
302M
2.3B
2B
1.5B
2.1B
15.1B
15.3B
15.9B
17.9B
19.3B
19.9B
19.1B
19.6B
27.9B
22B
9B
7.8B
6.6B
20.5B
15.4B
18.9B
16.5B
11.4B
12.2B
12.4B
6.5B
7.7B
9B
8.1B
9.5B
13.1B
15.2B
15.7B
18.5B
3.4B
4B
3.8B
3.1B
9.7B
8.6B
11.6B
7.6B
7.3B
9.8B
11.9B
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287
1,740,561,287

SEC Filings

ABT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

April 29, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 27, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

April 17, 2026
April 10, 2026
2026
8-K

8-K 2026

N/A

April 16, 2026
April 16, 2026
2026
8-K

8-K 2026

N/A

March 23, 2026
March 23, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 13, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

March 09, 2026
March 09, 2026
2026
8-K

8-K 2026

N/A

February 26, 2026
February 23, 2026
2026
10-K

10-K 2025 FY

FY

February 20, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 20, 2026
February 20, 2026
2026
Showing 1 to 10 of 484 filings